INTRODUCTION
For more than 60 years oxygen therapy has been used in Child Healthcare 1 , increasingly in chronic respiratory failure. 2 The use of long-term home oxygen therapy (LTOT) in children raises specific recommendations [3] [4] [5] [6] [7] [8] regarding its use following case reviews 2, 5 and national studies. 9 The use of home oxygen therapy reduces hospital costs, leads to an earlier hospital discharge and reduces healthcare-related infections. 10 LTOT specific and complex paediatric prescription, the range of related pathologies and associated costs determine the need for coordination in reference centres.
The increase of LTOT in children is associated to survival both of severely premature infants, some with bronchopulmonary dysplasia and of severely affected patients with chronic lung disease. 4, 6 Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com Oliveira L, et al. Long-term home oxygen therapy in children, Acta Med Port 2014 Nov-Dec;27 (6) : [717] [718] [719] [720] [721] [722] [723] [724] [725] The support systems for technology-dependent children allow for monitoring of clinical parameters and therapeutic adequacy, preventing the patient from having to attend to the hospital and reducing the number of hospital admissions. Dynamic interaction with the family at home allows for family preparation and technical support to be provided.
There are well-defined LTOT prescription criteria in adult patients, 11 which are more complex in children, due to wider range and complexity of pathologies. In Portugal, unlike the UK, 6 France 3 or Brazil, 2 there are no studies showing the characteristics of LTOT in children. These would allow for a better knowledge of the national reality and would promote healthcare adequacy and allow for specific paediatric clinical guidelines to be established. There are also clinical guidelines in Spain on clinical indications, methodology and follow-up. 7 In Portugal, the guideline (Norma de Orientação Clínica (NOC)) from the Direção Geral de Saúde (DGS) for oxygen therapy prescription (018/2011) 11 includes some aspects regarding children therapy but is not specific for children.
A national prescription system was started in the UK in 2006 12 allowing for the characterisation of the paediatric population on LTOT which in turn was used to establish clinical guidelines. 7, 8 Our study aimed to characterise paediatric patients on LTOT followed by a Paediatric Lung Unit at a Tertiary Hospital over a decade (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) and to compare the demographic characteristics and pathologies with a study carried out at the same unit, also over a decade, from 1991 to2000. The study's secondary objectives included the analysis of compliance to international and national recommendations and the determination of the need to establish national paediatric recommendations.
MATERIAL AND METHODS
This was a retrospective and comparative study, based on the analysis of patient's clinical record. Our patients were selected from our unit's 2003-2012 clinical data. Data were analysed by independent observers not involved in the patient's clinical follow-up.
The following inclusion criteria were used: patients on continuous/sleep-time LTOT program upon therapeutic optimization, for at least three months. Age limits were not established. Patients who required episodic oxygen therapy during infectious exacerbations were excluded.
The following patient-related variables were analysed: gender, underlying pathology, prematurity history, comorbidities (gastroesophageal reflux disease, pulmonary hypertension, obstructive sleep apnea), age at start and duration of oxygen therapy. The types of respiratory failure (RF) were recorded (hypoxemic vs. global), as well as therapy regimens (continuous vs. sleep-time), oxygen delivery (liquid, concentrator, cylinder), interface options and need for ventilatory support at home. The criteria used in LTOT prescription and patient's monitoring (body weight evolution and pulse oximetry) were recorded. Weight gain adequacy, discontinuation of oxygen therapy and final destination (discharge, follow-up, dropout, death) were considered as outcome markers. Patient's time of follow-up was analysed.
The following groups of diagnosis were considered, according to international experience 3, 4, 7, 8 and to our Department's experience: 5 broncho-pulmonary dysplasia (BPD), defined by the need for oxygen by a premature infant after 38-week gestational age or, in other words, starting on day 0 of chronological age; 11 was used and relevant omitted areas regarding the paediatric age were evaluated.
RESULTS
In total, 86 patients were followed over the 2003-2012 timeframe, 51 males (59.3%), discharged to the LTOT program. All patients were followed by the Home Mobile Support Unit (UMAD).
BPD was the main diagnosis (46 patients; 53.5%), followed by BO (12; 14.0%), mostly post-infectious, related to graft vs. host disease upon bone marrow transplant; neurological disorder (nine; 10.5%): four patients with cerebral palsy (three patients with hypoxic-ischaemic encephalopathy, one with lissencephaly), two with neurometabolic disease, one with Steinert myotonic dystrophy syndrome and BPD, one with type-I spinal atrophy and one with Rett syndrome and severe epilepsy. From the remaining patients, seven (8.1%) had CF, five (5.8%) had polymalformative syndromes (facial and cleft palate malformation, myelomeningocele, ArnoldChiari malformation and laryngotracheomalacia) and three patients with chromosomopathies; SCA (three patients; 3.5%); other neonatal RD (two patients; 2.3%): pulmonary hypoplasia and severe pneumonia outcome and IPD (two patients; 2.3%): neuroendocrine cell hyperplasia of infancy and cellular interstitial pneumonitis in infants (Table 1 ).
In addition to the patients with BPD, seven other patients were premature (four patients with BO, one with neonatal RD, one with neurometabolic disorder and one with a polymalformative syndrome). Twenty one patients (25.0%) had comorbidities: gastroesophageal reflux (14 patients; 16.2%), pulmonary hypertension (four patients; 4.7%) and obstructive sleep apnea (three patients; 3.4 %).
Median LTOT starting age was zero (0-216) months, due to the frequency of patients with BPD (46 patients; Oliveira L, et al. Long-term home oxygen therapy in children, Acta Med Port 2014 Nov-Dec;27(6):717-725 53.5%). Median duration of LTOT use was 13.5 months. Considering a 12-month limit, we found that most patients (65 patients; 75.6%) started on LTOT on the first year of life and 72 (83.7%) before 36 months of age. Seven patients with CF started on LTOT later, as well as three patients with SCA, two patients with BO and two patients with neurological disease (Table 1) .
A predominance of hypoxemic RF was found (71; 82.6%); the patients with CF and neurological disorders were predominant in global RF (15; 17.4%) ( Table 2) .
Continuous LTOT was predominant (74; 86.0%), while 12 patients (14.0%) were on sleep-time only prescription (Table 3) .
Single liquid oxygen was the main delivery source used (60; 69.8%); nine patients (10.5%) were on cylinderdelivered oxygen and 11 (12.8%) were on both; seven patients (8.1%) were on concentrator-delivered oxygen. Eyeglasses were more frequently used (58; 67.4%), followed by nasopharynx cannula (24; 27.9%) ( Table 3) . Non-invasive ventilation (NIV) was used in twelve (14.0%) patients in addition to LTOT related to persistent hypoxemia and/or hypercapnia, mostly through a bi-level pressure mask (eight patients; 61.5%). The patients on NIV had mostly a neurological disorder (five patients) ( Table 3) . We were able to obtain the prior arterial blood gas (ABG) levels on nine patients with a median pH of 7.33 (7.21-7 .34) and a median pCO 2 of 69.5 mmHg (55.2-89.6).
As regards LTOT starting time, monitoring and outcome criteria, 73 patients (84.9%) presented with a body weight below the 5 th percentile at the beginning of the study and 30 patients of this same group grew above that limit at the end (Table 4) . We did not find any differences regarding weight gain between the different groups of patient disorders (p = 0.195). Home pulse oximetry was used in six patients (6.9%). LTOT was discontinued in 38 patients (44.2%) ( Table 4) . By the end of the study, 12 BO associated to rheumatic fever and pulmonary hypertension; three neurological patients: type-I spinal atrophy, brain paralysis with hypoxic-ischaemic encephalopathy, Rett syndrome and severe epilepsy; four patients with CF and two with polymalformative syndromes.
Median follow-up time was 39.5 ( . We should note that three patients with CF, two with neurological pathology and one patient with BO were still on follow-up over the age of 18..
Comparison between two decades of LTOT
When compared to the 1991-2000 decade, 5 we should note the following methodological differences: threemonth minimum LTOT duration for inclusion in the study (in the previous study, one-month was established for BPD patients); patients with complex cardiac pathology were included in the polymalformative syndrome group of patients (in to the absence of isolated cardiac disease); lack of representativeness regarding primary pulmonary hypertension.
We wish to emphasize the inclusion of neurological and haematological patients and the increase in the number of patients with BPD and BO (Table 5) . We should also remark upon a similar distribution regarding the age of oxygen therapy onset by different pathologies, with longer duration in the patients with BDP over the most recent period of time (p = 0.025) ( Table 6 ).
Paediatric Guidelines and DGS (Portuguese Direcção Geral da Saúde) Guideline
We carried out a survey of paediatric guidelines for LTOT in France, 3 Brazil, 4 United Kingdom 6, 8 and Spain. 7 Major differences regarding paediatric LTOT prescription relate to evaluation, prescription, monitoring and outcome 6 which are favourable in children, except for CF and neuromuscular diseases. The following were the other major differences related to the use of LTOT in children: 1) available discontinuation of oxygen therapy as the patient grows and the need for sleep-time oxygen (below the daily 15-hour considered for the adult patient); 2) importance assigned to neuro-behavioural growth and development, particularly in children aged below three; 3) preferred monitoring with pulse oximetry instead of ABG levels; 4) prescription of intermittent LTOT with SpO 2 below 90% beyond 5% of 11 describes some of these differences and recommends the need for a specialized follow-up of these patients; however, the information is scarce and scattered. The indicators for assessment of the guideline application are not applicable to the entire range of paediatric age. The lack of a flowchart, as well as the lack of specific diagnosis in younger children is also a potential limitation. The limits of prescription, although slightly different in different guidelines, establish additional oxygen to be prescribed in patients with BPD and other neonatal RD for SpO 2 ≥ 93%; SpO 2 > 90% is considered in CF patients and SpO 2 > 94% in SCA patients. 4, 6, 7 The monitoring plan is mainly different in infants with chronic pulmonary diseases, with an indication for strict supervision and monitoring, at home and in the hospital, in order to determine oxygen flows.
Neurological disorder
3,4,6,7 Two visits are planned over the first week upon discharge and subsequently not beyond 3-4 weeks apart. 4, 6 Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com Oliveira L, et al. Long-term home oxygen therapy in children, Acta Med Port 2014 Nov-Dec;27(6):717-725
DISCUSSION
Our group of patients comprises a large sample of paediatric patients on LTOT with a wide range of disorders. We found a slight predominance of male patients, in line with other authors.
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Most patients started on LTOT during the first year of life, following a higher prevalence of neonatal diagnosis. We found, as previously, two different age group-peaks at LTOT onset. Early LTOT-related diagnosis in children were the most frequent and were predominantly associated to premature babies or to congenital malformations, inducing a zero median age, when compared to the group of patients with a later LTOT onset. This is one of the major distinction factors of LTOT in paediatric age.
The patients that started on LTOT after 36 months of age presented with pathologies that occurred later on, like post-infectious OB, or that occurred as a consequence of disease progression, due to deterioration of lung function and/or due to deterioration of tissue oxygen delivery (CF, SCA and neurological disorders). The median age at LTOT onset and duration remained unchanged during the study timeframe, with the exception of patients with BPD (p = 0.025) which showed a selection bias: a one-month minimal LTOT duration was considered in the previous study while three months were considered in the present study. However, this would be an expected difference due to the lower gestational age considered in the current study, in line with the general tendency towards the reduction of survival limit of premature babies.
BPD was the main diagnosis for LTOT and also the group with the higher number of patients who discontinued LTOT (35 patients; 80.4%), as observed in the United Kingdom and in Wales. 9 The 9% increase of prematurity in Portugal, 13 with strategies increasing preterm survival, 14 increased the number of patients with BPD.
14 LTOT is considered in these patients with SpO 2 ≤93% and no severe hypercapnia. 4, [6] [7] [8] In these patients, LTOT is also considered as a determinant factor for reducing sudden death in infants, 4, 6, 7, 16 the frequency of intermittent desaturations 6, 7, 16 and pulmonary hypertension 6, 7 and for growth 7, [16] [17] [18] and neurodevelopment promotion. 7, 16 As in premature infants, oxygen is especially toxic, as shown in previous studies (STOP-ROP and BOOST); 20,21 a SpO 2 95% maximum limit was established in order to reduce the incidence of retinopathy and BDP itself.
14 In our study, 51.0 months was the maximum duration of oxygen therapy in these patients; comorbidities such as laryngotracheomalacia, gastroesophageal reflux, recurrent aspiration, CF and congenital cardiac disease must be excluded when the need for LTOT persists upon the 12-month period. 6 Mortality in BPD was low (4.3%), mainly due to prematurity-related comorbidities.
The second most frequent diagnosis was BO, different from the previous study, 5 in line with the national tendency,
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followed-up in specialized units as in other countries. 2, 8 BO occurs later on, as it is frequently acquired upon infection with adenovirus. In this case, outcome is usually favourable and approximately half of the patients are independent from LTOT by the end of the study. The neurological pathology was the third more frequent diagnosis found, in line with the increasing indications for LTOT, as described in other European countries. 3, 7, 9 The need for LTOT in these patients relates to lung disease associated to aspiration pneumonia, gastroesophageal reflux, inefficient cough and thoracic deformity. 4, 7 We found an association to NIV in five patients due to chronic hypoventilation induced by ventilatory changes.
Síndromes polimalformativas

7
In neurological patients, LTOT has an indication in nonprogressive mild situations, as well as in patients where hypoxemia occurs despite NIV. 4 Mortality is high (33.3%), in line with what has been described by other authors.
The improvement in respiratory and nutritional care in CF may explain the relative reduction of LTOT in the paediatric age, due to an observed delay in respiratory failure onset. 23 A study carried out in Brazil 2 showed CF as main indication for LTOT. However, the adequate time for starting LTOT is not defined and there are no guidelines for screening nocturnal hypoxemia. 24 This group 4 suggests the use of COPD adult patients LTOT criteria in adolescent patients (PaO 2 ≤ 55 mmHg or SpO 2 ≤ 88%; PaO 2 56-59 mmHg or SpO 2 89% in the presence of cor pulmonale) and BPD criteria in infants (SpO 2 ≤ 93%). The frequency of desaturations is not directly related to the severity of pulmonary disease, to its progression, to the frequency of hospital admissions or to mortality, although it may have an influence on school performance. In our group of patients, LTOT was successfully discontinued in one patient upon lung transplant. Despite therapeutic and technological advances, CF remains a severe disease associated to multiorgan complications, reflected in the high mortality observed in the group of patients on LTOT (57.1%).
Polymalformative syndromes present early LTOT onset (0 -7 months) and long-term duration (9 -46 months). The complexity of these pathologies is also associated to a high mortality (40.0%).
Follow-up of patients with SCA in specialized centres, already suggested in international guidelines 24 and the potential benefits of LTOT in this group of patients explain for the inclusion in the study. The prescription of LTOT due to intermittent hypoxemia reduces the risk of stroke, painful episodes, secondary pulmonary hypertension and mortality. 6 According to the British guidelines, 6 nocturnal SpO 2 should be determined with ronchopathy or nocturnal enuresis after the age of 6 years; annual evaluation of SpO 2 in stable children is also recommended, with an indication for nocturnal monitoring when < 95%. The mechanism for desaturation is not fully understood, possibly related to low haemoglobin values and subsequent right shift of the haemoglobin dissociation curve or with the presence of carboxy and metahaemoglobin. 25, 26 SpO 2 levels may be overestimated and unreliable 26, 27 and therefore they should be obtained in sleep and awake time; when < 93%, PaO 2 should be considered: if < 70 mmHg, LTOT should be considered. 4 The need for LTOT depends on disease's progression and consequently in the late onset group LTOT was not discontinued in any patient over the study period.
One of the patients presented with concomitant obstructive sleep apnea, with the need for NIV until adenotonsillectomy was performed.
One patient with pulmonary hypoplasia and the consequences of a severe pneumonia (other neonatal RD group) was included in the study. The same oxygen therapy onset criteria as for BPD patients are used in these patients, as infants are predominantly affected. 6 Both situations presented with short follow-up time, the need for LTOT persisting at the time of data collection (5 to 13-months duration). Although none of the patients remained independent from LTOT, studies show that discontinuation of oxygen therapy is frequent upon 12 to 28 months (14 -66 months). 28, 29 IPD were represented by two patients in our study (one with neuroendocrine cell hyperplasia of infancy and one with unspecific cellular interstitial pneumonitis). Gas exchange impairment leads to oxygen supplementation during variable periods of time, while directed therapy is carried out.
The use of oxygen-delivery equipment, monitoring and evaluation of supplementary oxygen flow in paediatric patients on LTOT has some differences, when compared to adult patients, as described below.
We found a predominance of liquid oxygen supply. These portable devices allow for patient's deambulation and are easily recharged at home. 4 Their main disadvantage regards its high cost. 4, 6, 7 The use of cylinder-delivered oxygen is a more affordable alternative, although less functional due to its volume and the need for frequent recharges, making autonomy and deambulation more difficult, a crucial factor for most of these children, with a predicted normal functioning in the future. 7 The use of a concentrator is also an alternative, 4 not often used in children, as it allows for scarce mobility, depends on electrical power and is noisy.
Delivery systems and interfaces include eyeglasses, nasopharynx cannula and face masks. In our study, nasal cannula (eyeglasses and nasopharynx cannula) were mostly used, in line with what was described by other authors.
2 Nasal cannula are the preferred method due to its comfortable use. They need to be frequently changed, 4 with daily cleaning and they avoid the waste of oxygen and make communication and food intake easier. 6, 7 Cannula are uncomfortable to use with flows > 2 l/min, where face masks are preferrable. 4, 6, 7 The choice depends on the pathology and on the need for oxygen and it may involve parent's preference. 6 Monitoring of paediatric patients on LTOT includes the frequent evaluation and survey of the consequences of chronic hypoxemia and should be different from those used in the adults 3, 6, 7 as change in growth and cognitive development are the more relevant consequences, in addition to the usual increases in haematocrit levels, pulmonary hypertension and right ventricular hypertrophy. In French guidelines 3 the evaluation of chronic patients during sleep-time (6 -12h) and during activity-time is suggested; in addition, day-time CO 2 level should also be Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com Oliveira L, et al. Long-term home oxygen therapy in children, Acta Med Port 2014 Nov-Dec;27(6):717-725 monitored and, when normal, also the night-time CO 2 level. In children below two years of age, the presence of SpO 2 < 93% and/or above 5% of sleep-time below 90% and/or the presence of pulmonary hypertension is considered as an indication for LTOT while in children above two years of age, a level of SpO 2 < 90% or more than 10% of sleep-time below 90% and/or the presence of pulmonary hypertension are suggested and SpO 2 > 94% or > 92%, with or without the presence of pulmonary hypertension, respectively, as LTOT target levels. In our study, monitoring included pulse oximetry in an outpatient or home visit regimen and anthropometric evolution. ABG levels were obtained in a scarce number of patients underlying that, unlike adult patients on LTOT, ABG levels should not be used as criteria for LTOT prescription in the paediatric age. The type of oximeter used 6 should be known (fractional or functional oxygen saturation) 6 as well as its limitations. 4 The use of outpatient pulse oximetry will not benefit the paediatric patient on LTOT 6 and was previously reviewed. 30 Regarding the anthropometric evolution, 30 patients reached above the 5th percentile during LTOT (34.9%), showing its importance and overall benefit.
Due to its specificities, paediatric patients on LTOT should have the support of a homecare specialized team. Although beyond the aim of our study, we should remark that patients on LTOT at our unit are weekly visited by the Home Mobile Support Unit (UMAD). This is the result of a 9-year institutional partnership between the Fundação do Gil and the Hospital de Santa Maria allowing for a periodical visit from a hospital nurse. As the number of paediatric patients with respiratory technical healthcare is lower when compared to the group of adult patients and due to a wider range of pathologies, we believe in the benefit of a home visit based on the hospital that is following the patients. The monitoring visits to these patients include the evaluation of SpO 2 level on ambient air and on oxygen. 4 In one study 31 involving 55 children with BPD and the evaluation of home healthcare, 41% of children needed to be readmitted, with nine-day median hospital stay. LTOT discontinuation should be considered with supplementary oxygen < 0.1 L/min, using the target saturations that lead towards this therapy. 4, 6, 7 It is the rule in BPD, as well as in IPD and BO. 4, 6 In our study, LTOT was discontinued in 38 patients (44.2%). According to the situation, LTOT discontinuation may initially start with a nocturnal regimen or start as a 24h regimen and there is no consensus regarding which is the best strategy. 4, 6, 8 The equipment should remain at the patient's home for at least three months following discontinuation, upon which an evaluation with pulse oximetry should be carried out on two occasions, approximately one-month apart as well as an evaluation of child's growth. 4 We should also mention the importance of follow-up of these patients beyond 18 years of age, namely patients with CF, neurological pathology and BO, due to the characteristics and difficulties of the transition of these chronic patients to adult medicine. A time of overlapping follow-up is beneficial for patients, allowing for a progressive adaptation of the patient and his family to the new reality. For this reason, we have included in our study patients that exceeded paediatric age but are still followed at our Unit.
Due to its retrospective and long-term nature, record reliability is one of the limitations of our study. Not all the patients followed the same guidelines or constant examination regimens. The presence of a structured system of prescription, which is crucial for this therapy, would answer this limitation. As regards the two-decade comparison, the various nosological groups prevent a direct comparison. In addition, BPD inclusion criteria were different, representing a selection bias.
CONCLUSIONS
In line with international and previous descriptions, paediatric patients with BPD are those who benefit the most from LTOT programs, with a favourable outcome and a possibility of discontinuation. The improvement in healthcare of the patient with CF leads to a reduction in the number of paediatric patients on LTOT. The inclusion of new groups of diagnosis may allow for firmer conclusions based on the analysis of a larger patient pool).
The specific paediatric use of LTOT, when compared to adults, imposes higher resource consumption due to the dynamic of growth and to the wide range of pathologies related to LTOT.
A homogeneous and consistent LTOT prescription system would allow for a national record database to be created, including the characterisation and knowledge of the paediatric population on LTOT; this would lead to homogeneity in criteria and prescription systems.
The authors suggest specific paediatric guidelines in this domain and hope that more reliable national records will allow for the implementation of an adequate healthcare plan.
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